LSV Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $451M | Sell |
2,386,840
-69,117
| -3% | -$12.1M | 0.97% | 17 |
|
|
2025
Q4 | $418M | Sell |
2,455,957
-55,901
| -2% | -$8.57M | 0.91% | 19 |
|
|
2025
Q3 | $331M | Sell |
2,511,858
-41,884
| -2% | -$5.02M | 0.73% | 34 |
|
|
2025
Q2 | $271M | Buy |
2,553,742
+87,576
| +4% | +$9.51M | 0.63% | 42 |
|
|
2025
Q1 | $306M | Sell |
2,466,166
-64,884
| -3% | -$8.46M | 0.73% | 27 |
|
|
2024
Q4 | $312M | Buy |
2,531,050
+37,108
| +1% | +$4.37M | 0.72% | 31 |
|
|
2024
Q3 | $278M | Buy |
2,493,942
+13,379
| +0.5% | +$1.47M | 0.6% | 47 |
|
|
2024
Q2 | $265M | Buy |
2,480,563
+99,705
| +4% | +$11M | 0.58% | 48 |
|
|
2024
Q1 | $287M | Buy |
2,380,858
+37,631
| +2% | +$4.61M | 0.59% | 46 |
|
|
2023
Q4 | $288M | Sell |
2,343,227
-28,950
| -1% | -$3.61M | 0.63% | 40 |
|
|
2023
Q3 | $307M | Buy |
2,372,177
+55,630
| +2% | +$7.41M | 0.71% | 31 |
|
|
2023
Q2 | $287M | Sell |
2,316,547
-1,856
| -0.1% | -$250K | 0.63% | 37 |
|
|
2023
Q1 | $339M | Buy |
2,318,403
+262,509
| +13% | +$38.8M | 0.76% | 26 |
|
|
2022
Q4 | $328M | Buy |
2,055,894
+294,917
| +17% | +$43.2M | 0.72% | 27 |
|
|
2022
Q3 | $235M | Buy |
1,760,977
+29,284
| +2% | +$4.45M | 0.55% | 51 |
|
|
2022
Q2 | $270M | Sell |
1,731,693
-76,299
| -4% | -$11.7M | 0.58% | 46 |
|
|
2022
Q1 | $281M | Sell |
1,807,992
-29,084
| -2% | -$4.22M | 0.52% | 57 |
|
|
2021
Q4 | $234M | Sell |
1,837,076
-41,190
| -2% | -$5.41M | 0.41% | 80 |
|
|
2021
Q3 | $245M | Sell |
1,878,266
-97,550
| -5% | -$14.7M | 0.44% | 69 |
|
|
2021
Q2 | $351M | Sell |
1,975,816
-96,555
| -5% | -$16.7M | 0.6% | 41 |
|
|
2021
Q1 | $341M | Sell |
2,072,371
-197,156
| -9% | -$32.4M | 0.58% | 40 |
|
|
2020
Q4 | $375M | Sell |
2,269,527
-171,430
| -7% | -$25.5M | 0.68% | 32 |
|
|
2020
Q3 | $348M | Buy |
2,440,957
+215,526
| +10% | +$26.7M | 0.71% | 30 |
|
|
2020
Q2 | $246M | Buy |
2,225,431
+363,015
| +19% | +$40.1M | 0.51% | 51 |
|
|
2020
Q1 | $186M | Sell |
1,862,416
-3,503
| -0.2% | -$453K | 0.45% | 55 |
|
|
2019
Q4 | $279M | Buy |
1,865,919
+144,628
| +8% | +$19.7M | 0.43% | 68 |
|
|
2019
Q3 | $221M | Buy |
1,721,291
+594,171
| +53% | +$79.6M | 0.36% | 82 |
|
|
2019
Q2 | $161M | Buy |
1,127,120
+125,470
| +13% | +$16.9M | 0.26% | 112 |
|
|
2019
Q1 | $143M | Buy |
1,001,650
+237,190
| +31% | +$30.9M | 0.23% | 124 |
|
|
2018
Q4 | $94.8M | Buy |
764,460
+466,168
| +156% | +$69.2M | 0.17% | 158 |
|
|
2018
Q3 | $50.2M | Buy |
298,292
+9,956
| +3% | +$1.71M | 0.08% | 257 |
|
|
2018
Q2 | $49.7M | Buy |
288,336
+57,666
| +25% | +$9.43M | 0.08% | 251 |
|
|
2018
Q1 | $34.8M | Buy |
230,670
+71,100
| +45% | +$10.4M | 0.06% | 287 |
|
|
2017
Q4 | $21.5M | Buy |
159,570
+26,740
| +20% | +$3.71M | 0.03% | 365 |
|
|
2017
Q3 | $19.4M | Buy |
132,830
+45,630
| +52% | +$6.9M | 0.03% | 378 |
|
|
2017
Q2 | $13.6M | Buy |
+87,200
| New | +$13.3M | 0.02% | 418 |
|
|
2016
Q3 | – | Sell |
-1,784
| Closed | -$252K | – | 1063 |
|
|
2016
Q2 | $252K | Buy |
+1,784
| New | +$263K | ﹤0.01% | 930 |
|
Other funds holding JAZZ
VPM
VCM
EC
LSV Asset Management's JAZZ Position: Q1 2026 in Review
LSV Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.8% in Q1 2026, selling an estimated $12.1M and leaving 2,386,840 shares worth $451M. The position accounts for 0.97% of the portfolio, ranked #17.
LSV Asset Management first reported a position in JAZZ in Q2 2016 and has held it in 37 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- LSV Asset Management held 2,386,840 shares of Jazz Pharmaceuticals worth $451M as of Q1 2026.
- LSV Asset Management sold 69,117 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12.1M.
- Jazz Pharmaceuticals made up 0.97% of LSV Asset Management's portfolio in Q1 2026, its #17 holding.
- LSV Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 37 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on LSV Asset Management's 13F filing for Q1 2026, filed 11 May 2026.